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Twist1 is highly expressed in primary and metastatic non-small cell lung cancer (NSCLC), and thus acts as a critical target for
lung cancer chemotherapy. In the current study, we investigated the underlying mechanism initiated by silencing of Twist1 that
sensitizes NSCLC cells to cisplatin. Silencing of Twist1 triggered ATP depletion, leading to AMP-activated protein kinase
(AMPK)-activated mammalian target of rapamycin (mTOR) inhibition in NSCLC cells. AMPK-induced mTOR inhibition, in turn,
resultedindownregulationofribosomeproteinS6kinase1(S6K1)activity.DownregulationofmTOR/S6K1reducedMcl-1protein
expression, consequently promoting sensitization to cisplatin. Overexpression of Mcl-1 reduced PARP cleavage induced by
cisplatin and Twist1 siRNA, suggesting that this sensitization is controlled through Mcl-1 expression. Interestingly, cells treated
with Twist1 siRNA displayed upregulation of p21
Waf1/CIP1, and suppression of p21
Waf1/CIP1 with speciﬁc siRNA further enhanced
the cell death response to cisplatin/Twist1 siRNA. In conclusion, silencing of Twist1 sensitizes lung cancer cells to cisplatin via
stimulating AMPK-induced mTOR inhibition, leading to a reduction in Mcl-1 protein. To our knowledge, this is the ﬁrst report
to provide a rationale for the implication of cross-linking between Twist1 and mTOR signaling in resistance of NSCLC to
anticancer drugs.
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Lung cancer remains the leading cause of cancer-related
death worldwide. About 80% of all lung cancers are non-small
cell lung cancer (NSCLC), including squamous carcinoma,
adenocarcinoma and large cell carcinoma, with 450% of
these patients presenting with locally advanced or metastatic
disease.
1 The 5-year survival rates for advanced NSCLC are
only 10–20%, partly due to advanced metastasis.
2 Cisplatin is
a commonly used therapeutic agent for advanced NSCLC.
However, resistance to cisplatin is a major obstacle in
potentially curative treatments for advanced NSCLC.
3
The mammalian target of rapamycin (mTOR) is a highly
conserved serine/threonine kinase that regulates cell growth,
cell cycle progression and metabolism. The phosphatidylino-
sitol-3kinase/AKTsignalingpathwayactivatesmTOR,inturn,
directly phosphorylating ribosome protein S6 kinase 1 (S6K1)
andeIF4E-bindingprotein1,bothofwhichareimportantinthe
control of protein translation initiation.
4–6 S6K1 phosphory-
lates S6, which regulates the translation of 50 terminal
oligopyrimidine mRNAs that encode ribosomal proteins and
translation factors. 4EBP1 binds to and prevents eIF4E,
initiating cap-dependent translation. mTOR is constitutively
activated in a variety of human cancers, including ovarian,
pancreatic,aswellaslungcarcinoma.
7Thus,mTORsignaling
networks have emerged as attractive targets in novel
therapeutic anticancer strategies.
Epithelial-to-mesenchymal transition (EMT) is a fundamen-
tal biological process by which epithelial cells are converted to
mesenchymal cells during embryonic development. This
process is characterized by loss of cell polarity, decrease in
cell–cell adhesion and gain in migration ability. Recently, the
concept of EMT has been extended to tumor migration,
invasion and metastasis.
8,9 The EMT process is controlled by
zinc-ﬁnger proteins (Snail, Slug, Zeb1 and Zebs/SIP1) and
basic helix-loop-helix factors (Twist and E47).
10
Twist is an important inducer of EMT, which downregulates
the epithelial cell marker (E-cadherin) and upregulates
mesenchymal markers (ﬁbronectin, N-cadherin and vimentin),
and promotes cancer invasion and metastasis.
11,12 Twist
expression promotes resistance to apoptosis when cells are
challenged with cisplatin in lung and bladder cancer and
paclitaxel in prostate cancer.
13 Accordingly, identiﬁcation of
the upstream activators and downstream targets of Twist1
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cancer. In the present study, we showed that knockdown of
Twist promotes or sensitizes lung cancer cells to apoptotic
death via decreasing mTOR/S6K1-dependent Mcl-1 transla-
tion that allows cisplatin to exert its toxic effect. These results
suggest that targeting molecular cross-talk between mTOR
and EMT regulators may be an effective approach to combat
cancer.
Results
Knockdown of Twist1 enhances cisplatin-induced cell
death in NSCLC. Twist1 is highly expressed in primary and
metastatic NSCLC,
14 and therefore an attractive therapeutic
target for lung cancer. Initially, we investigated whether
downregulation of Twist1 enhances cisplatin sensitivity in
NSCLC cells. Two lung cancer cell lines, A549 and H1299,
expressed high levels of Twist1 (Figure 1b), consistent with
previous reports.
14 A549 and H1299 cells were transfected
with Twist1 siRNA and exposed to cisplatin at doses of 8 and
6mM for 24h, respectively. At these concentrations of
cisplatin, the growth inhibitory effects o20% (Figure 1a).
The two Twist1 siRNAs led to a considerable knockdown of
mRNA expression in both cell types (Figure 1b). Twist1
suppression with siRNAs induced a sensitization effect to
cisplatin (Figure 1c) and enhanced PARP cleavage
(Figure 1d). Our results clearly indicate that suppression of
Twist1 effectively enhances the sensitivity of NSCLC cells to
cisplatin.
Knockdown of Twist1 enhances cell sensitivity to
cisplatin through Mcl-1 downregulation. Next, we deter-
mined the effect of Twist1 knockdown on clonogenic survival.
As shown in Figure 2a, colony formation was signiﬁcantly
reduced in cells transfected with Twist1 siRNA, compared
with control siRNA. Silencing Twist1 expression with siRNA
had no effect on the expression of EMT-related proteins,
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Figure 1 Knockdown of Twist1 enhances NSCLC cell sensitivity to cisplatin. (a) A549 and H1299 cells were treated with the indicated concentrations of cisplatin for 24h.
Cell viability was measured with the MTT assay. The viability of control cells was set at 100%, and survival relative to the control presented. (b) A549 and H1299 cells were
transfectedwithtwodifferentTwist1orcontrolsiRNAsfor30h.Twist1mRNAlevelsweremeasuredusingRT-PCRanalysis.(candd)A549andH1299cellsweretransfected
with siCTL or siTwist1 for 20h, followed by 8 (A549 cells) or 6mM (H1299 cells) cisplatin for 24h. Cell viability was measured with the MTT assay (c) and protein levels
determined using westernblot analysis(d). Data shownare representative of three independent experiments. All graphsare shown as themean of each groupand error bars
represent S.D. **Po0.01 versus the siCTL/cisplatin-treated group or siTwist1-treated group
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Cell Death and Diseasesuch as N-cadherin, a-catenin, b-catenin and vimentin
(Figure 2b), suggesting that chemosensitivity induced by
Twist1 downregulation is not related to EMT-related protein
expression. Recent studies showed that activation of AKT
(especially AKT2) by Twist1 is critical for the maintenance of
EMT and promotion of invasion
15,16 and activation of the
ERK pathway by EGF has profound feedback on EGFR
signaling, which activates EMT via the AKT pathway.
17 We
then investigated the effect of AKT and ERK activation in
cells with Twist1 siRNA. Silencing of Twist1 did not affect the
AKT and ERK activation, as assessed by the protein level of
p-AKT, p-ERK, AKT and AKT2 (Figure 2b). However,
expression of Mcl-1 protein was markedly decreased in cells
treated with Twist1 siRNA, compared with other Bcl-2
members, such as Bcl-xL and Bcl-2 (Figures 2b and c).
The survivin protein, unlike IAP family member, such as
XIAP, was also found to be slightly decreased in the
presence of Twist1 siRNA. Notably, downregulation of
survivin by Twist1 siRNA did not confer sensitivity to cisplatin
(data not shown). To understand how Mcl-1 downregulation
occurs in cells treated with Twist1 siRNA, we analyzed Mcl-1
mRNA expression using RT-PCR. No signiﬁcant differences
were detected among both cell types treated with control and
Twist1 siRNA (Figure 2c), excluding the possibility of
transcriptional regulation.
A recent study reported that NSCLC cell lines express high
levels of Mcl-1, and suppression of Mcl-1 induces signiﬁcant
celldeath.
18Asexpected,downregulationofMcl-1withsiRNA
induced cell death and PARP protein cleavage in our
experiments (Figures 3a and b). Colony formation was also
reduced in the presence of Mcl-1 siRNA, compared with
control siRNA (Figure 3c). To further establish whether Mcl-1
has an essential role in NSCLC survival, we transfected His-
tagged Mcl-1 plasmids in cells treated with Twist1 siRNA and
cisplatin. Twist1 siRNA or/and cisplatin-induced PARP
cleavage was reduced upon overexpression of Mcl-1
(Figure 3d). Our data indicate that downregulation of Mcl-1
iscriticalforthesensitizingeffectofTwist1siRNAoncisplatin-
induced cell death.
Knockdown of Twist1 leads to inhibition of mTOR
activity, which has an important role in Mcl-1 down-
regulation. Next, we investigated the mechanism by which
knockdown of Twist1 suppresses Mcl-1 protein expression.
Initially, mTOR activity was assessed in cells treated with
Twist1 siRNA. Twist1 siRNA induced suppression of mTOR
activity, as assessed based on the decrease in phosphoryla-
tion of mTOR and the mTOR effectors, S6K and S6, in H1299
cells (Figure 4a). A recent report showed that mTOR promotes
survival through translational control of Mcl-1.
19 Accordingly,
we analyzed the Mcl-1 protein level in cells treated with mTOR
siRNA. As expected, suppression of mTOR resulted in
decreased expression of Mcl-1 protein and enhanced H1299
cell sensitivity to cisplatin (Figures 4b and c).
S6K1,adownstreamtargetofmTOR,hasimportantrolesin
cell proliferation, protein translation and cell survival and is
thus an effective target for cancer therapy.
20 To ascertain
whetherS6K1isinvolvedintheregulationofMcl-1expression
and consequent cell survival, we transfected cells with S6K1
siRNA, followed by treatment with cisplatin. S6K1 siRNA
induced a decrease in Mcl-1 protein, relative to control siRNA
(Figure 5a). Moreover, knockdown of S6K1 enhanced
cisplatin-induced cell death (Figures 5b and c). Overexpres-
sion of S6K1 reduced PARP cleavage induced by Twist1
siRNA (Figure 5d). Based on these results, we propose that
mTOR activity is suppressed upon Twist1 knockdown, which
is critical for Mcl-1 downregulation.
Knockdown of Twist1 leads to inhibition of mTOR
activity through AMP-activated protein kinase (AMPK)
activation. mTOR activity is suppressed under conditions of
energy deprivation in which depleted ATP levels trigger
AMPK activation.
21 We further investigated whether AMPK is
involved in mTOR inhibition induced by Twist1 suppression.
As shown in Figure 6b, treatment with Twist1 siRNA
stimulated phosphorylation of AMPK and the AMPK sub-
strate, acetyl-CoA carboxylase, in A549 and H1299 cells.
Moreover, suppression of Twist1 led to a marked increase in
the cellular ADP/ATP ratio, indicating a decrease in the ATP
content in both cell types (Figure 6a). To establish the
involvement of AMPK in Twist1 siRNA-induced mTOR
inhibition, we transfected cells displaying Twist1 down-
regulation with AMPKa1/2 siRNA. Downregulation of AMPK
led to recovery of mTOR activity inhibited by Twist1 siRNA
(Figure 6c). Our results collectively suggest that silencing of
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Figure 2 Knockdown of Twist1induces a decreaseinMcl-1protein expression.
(a) H1299 cells were transfected with control or Twist1 siRNA for 24h. Cells were
reseededatadensityof2000cellsperwellinthree60-mmplates.Colonyformation
was monitored over the following 10 days. Colonies were stained using the
Diff-Quick kit. (b and c) A549 and H1299 cells were transfected with control or
Twist1siRNAfor30h.TheindicatedproteinandmRNAlevelsweremeasuredusing
western blot (b and c) and RT-PCR (c) analyses. Data shown are representative of
at least two independent experiments
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Cell Death and DiseaseTwist1 expression is associated with ATP depletion, leading
to AMPK-activated mTOR inhibition.
p21
Waf1/CIP1 downregulation triggers the cell death to
Twist1 siRNA and cisplatin. In view of the earlier ﬁnding
that increased p21
Waf1/CIP1 expression determines cisplatin
resistance in human testicular cancer,
22 we analyzed the
p21
Waf1/CIP1 mRNA and protein levels in NSCLC cells treated
with cisplatin. As shown in Figures 7a and b, cisplatin
induced an increase in the p21
Waf1/CIP1 mRNA and protein
levels in a dose-dependent manner. p21
Waf1/CIP1 upregula-
tion by cisplatin was observed, even in p53-defective H1299
cells, suggesting that cisplatin induces p21 expression in a
p53-independent manner. Interestingly, p21
Waf1/CIP1 was
additionally upregulated by Twist1 siRNA in both cell types,
as shown in Figure 7c. We further investigated whether
p21
Waf1/CIP1 has a protective role against cisplatin and/or
Twist1 knockdown-induced cell death by transfecting cells
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Figure 3 Mcl-1 is essential for NSCLC survival. (a and b) A549 and H1299 cells were transfected with control or Mcl-1 siRNA for 48h. Cell morphology images were
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Cell Death and Diseaseadministered with cisplatin and/or Twist1 siRNA with p21
Waf1/CIP1
siRNA. p21
Waf1/CIP1 depletion resulted in enhanced sensitiv-
ity of cells to Twist1 siRNA and cisplatin-mediated apoptosis
(Figure 7d), suggesting a role of p21
Waf1/CIP1 in preventing
cell death by cisplatin or Twist1 siRNA in NSCLC.
Discussion
In the present study, we demonstrated that: (1) knockdown of
Twist1 enhances cisplatin-induced cell death in NSCLC cells,
(2) antiapoptotic Mcl-1 is signiﬁcantly downregulated upon
knockdown of Twist1, (3) mTOR activity is suppressed upon
Twist1 knockdown, which has an important role in Mcl-1
downregulation, (4) ATP depletion and AMPK activation
induced by Twist1 siRNA induces mTOR suppression,
(5) p21
Waf1/Cip1 is upregulated in cells treated with cisplatin
and/orsiRNAtargetingTwist1and(6)suppressionofp21Waf1/
CIP1 potentiates cell death induced by cisplatin and/or Twist1
siRNA. To our knowledge, this is the ﬁrst report to show that
cross-talk between EMT regulators and mTOR signaling is
implicated in resistance to anticancer drugs in NSCLC.
Cisplatin is an effective anticancer drug widely used to treat
various solid tumors, including NSCLC. However, acquire-
ment of resistance is a primary impediment in cancer
treatment.
3 Knockdown of Twist1 with speciﬁc siRNA sensi-
tized A549 and H1299 NSCLC cells to cisplatin-induced cell
death. Our data are consistent with previous study, suggest-
ing that Twist depletion increases A549 cell sensitivity to
cisplatin.
23 This sensitizing effect was independent of the p53
status, because efﬁcient sensitization was observed in p53-
defectiveH1299cells. Mcl-1proteinexpression wasmarkedly
decreased in cells treated with Twist1 siRNA, compared with
other Bcl-2 members (Figure 2b). Overexpression of Mcl-1
suppressed cell death induced by the Twist1 siRNA and
cisplatin combination. These results indicate that down-
regulation of Mcl-1 has an important role in the sensitizing
effect ofTwist1 siRNAoncisplatin-induced cell death.Indeed,
Mcl-1 hasbeenshowntobeacritical survivalfactorinmultiple
myeloma as well as NSCLC.
18 Mcl-1 is a highly unstable
protein, requiring active protein synthesis to maintain its
expression levels.
24 In our experiments, knockdown of Twist1
reduced Mcl-1 protein, but not mRNA levels (Figure 2c).
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Cell Death and DiseaseThese results strongly suggest that dysregulation of transla-
tion machinery factors is involved in Mcl-1 downregulation by
Twist1 siRNA.
In this regard, we determined whether mTOR and its
downstream factors are involved in sensitization to cisplatin
induced by Twist1 knockdown. Unexpectedly, knockdown of
Twist1 led to reduced phosphorylation levels of mTOR and
S6K1, an mTOR downstream effecter. Downregulation of
mTOR and S6K1 with siRNA sensitized cells to cisplatin,
consistent with the previous ﬁnding that transfection of
cisplatin-resistant lung cancer cells with siRNA directed
against mTOR restores sensitivity.
25 Importantly, we showed
that knockdown of mTOR or S6K1 downregulates the Mcl-1
protein level, which is increased in cisplatin-resistant cells.
26
These results indicate that Mcl-1 is a downstream target of
mTORand S6K1.Furthermore, Mcl-1 mayberegulatedatthe
translational level, because the main function of mTOR is to
control translation via direct regulation of S6K1 and 4E-BP.
This assumption is supported by several lines of evidence
showing that Mcl-1 is a potential downstream target of eIF4E
that speciﬁcally contains a GþC-rich (470%) 50 untranslated
region among the antiapoptotic Bcl-2 members.
19,27,28 In
addition, inhibition of mTOR with rapamycin blocked Mcl-1
protein synthesis, but not that of Bcl-2 or Bcl-xL.
19
Surprisingly, knockdown of Twist1 led to a marked increase
in the ADP/ATP ratio, indicating a decrease in ATP content.
AMPKisacentralcellularenergy-sensingsystemthatactively
participatesintheinteractionbetweenmetabolismandcancer
via regulation of the mTOR pathway. AMPK activation directly
phosphorylates and activates TSC2 by enhancing its GAP
activity,leadingtoinhibitionofmTORsignaling.
29Ourﬁndings
conﬁrmed that knockdown of Twist1 led to AMPK activation
and consequently to mTOR inhibition. Downregulation of
AMPK using AMPKa1/2 siRNA counteracted the inhibition of
mTOR activity by Twist1 siRNA. In the present study, we
showed that silencing of Twist1 is associated with ATP
depletion, leading to AMPK-activated mTOR inhibition, high-
lighting a novel underlying mechanism of linking between the
Twist1 and mTOR pathways. However, further research is
necessary to clarify the precise mechanisms linking knock-
down of Twist1 to ATP-depletion-induced AMPK activation.
Several studies have reported that increased p21
Waf1/CIP1
expression is associated with tumor progression and negative
prognosis and is related to drug resistance in several tumor
types.
30,31 Our experiments revealed that cisplatin or silen-
cing of Twist1 upregulates p21
Waf1/CIP1 expression at the
transcriptional level. This p21
Waf1/CIP1 upregulation was
observed in p53-defective H1299 cells, and may thus be
independent of p53. Treatment of cells with p21
Waf1/CIP1
siRNA enhanced the sensitizing effect of Twist1 silencing on
cisplatin-induced cell death. These results indicate that
upregulation of p21
Waf1/CIP1 has a protective role against
cisplatin or/and Twist1 knockdown-induced cell death, sup-
porting the utility of p21
Waf1/CIP1 as a possible therapeutic
target, at least for cisplatin treatment, in NSCLC.
In conclusion, we have demonstrated that silencing of
Twist1 sensitizes lung cancer cells to cisplatin. This sensitiza-
tion is mediated by ATP depletion, resulting in AMPK
activation and mTOR/S6K1 inhibition, and culminating in
downregulation of the Mcl-1 protein level. Our ﬁndings
highlight a novel mechanism of sensitization to cisplatin-
induced cell death linking Twist1 to the mTOR pathway and
provide a rationale for the use of Twist1 as a promising
therapeutic target in lung cancer treatment.
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Cell Death and DiseaseMaterials and Methods
Cell cultures and reagents. H1299 and A549 cell lines were obtained from
the American Type Culture Collection (Manassas, VA, USA) and cultured in the
recommended growth medium (Invitrogen, Carlsbad, CA, USA) under 5% CO2 at
371C. cis-Diammineplatinum (II) dichloride was purchased from Sigma-Aldrich
(St. Louis, MO, USA).
Measurement of cell viability. Cell viability was determined by measuring
the mitochondrial conversion of 3-(4,5–dimethylthiazolyl–2)-2,5-diphenyltetrazo-
lium bromide (MTT) to a colored product. Following treatment of cells with drugs,
the MTT reagent was added. Next, cells were solubilized in DMSO. The amount of
converted MTT was determined by measuring absorbance at 570nm.
RT-PCR analysis. Total RNA isolation and cDNA synthesis were conducted,
as described previously.
32 The following primers were used: Twist1 (50-TGTCCG
CGTCCCACTAGC-30 and 50-TGTCCATTTTCTCCTTCTCTGGA-30, 93bp product),
Mcl-1 (50-TGCTGGAGTTGGTCGGGGAA-30 and 50-TCGTAAGGTCTCCAG
CGCCT-30, 212bp product),
33 p21
Waf1/CIP1 (50-ATGGAACTTCGACTTTGTCAC-30
and 50-AGAAATCTGTCATGCTGGTCT-30, 308bp product) and b-actin (50-GGAT
TCCTATGTGGGCGACGA-30 and 50-CGCTCGGTGAGGATCTTCATG-30, 438bp
product).
Plasmids and siRNAs. Full-length Mcl-1 cDNA was cloned into the BamHI/
XbaI sites of pcDNA4 HisMax C (Invitrogen) encoding His. S6K1 cDNA containing
an N-terminal Myc (plasmid 26610) was purchased from Addgene (Cambridge,
MA, USA). All constructs were veriﬁed by DNA sequencing.
Twist1 (no. 1, sc-38604), Mcl-1 (sc-35877), AMPKa1/2 (sc-45312), p21
(sc-29427) and control (no. 1, sc-37007) siRNAs were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA), Twist1 (no. 2, s14523) and control (no.
2, 4611) siRNAs from Ambion (Austin, TX, USA), S6K1 (Hs_RPS6KB1_5) and
control (1022076) siRNAs from Qiagen (Valencia, CA, USA) and mTOR (6381) and
control (6568) siRNAs from Cell Signaling Technology (Beverly, MA, USA).
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Figure 7 Knockdown of p21
Waf1/CIP1 promotes the cell death response to cisplatin and Twist1 siRNA. (a and b) A549 and H1299 cells were treated with the indicated
concentrations of cisplatin for 24h. (c) A549 and H1299 cells were transfected with control or Twist1 siRNA for 48h. (d) A549 cells were transfected with control, Twist1
or p21
Waf1/CIP1 siRNA for 24h, followed by treatment with 6mM cisplatin for 24h. The indicated protein and mRNA levels were measured using western blot (a, c and d) and
RT-PCR(b and c) analyses. Cell viability was measured with the MTT assay (d). Cell viability of control siRNA (siCTL)-treated group was set at 100%, and survival relative to
the siCTL presented. The graph is shown as the mean of each group and error bars reﬂect S.D. *Po0.05 versus the siTwist1/cisplatin-treated group
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Cell Death and DiseaseTransfection experiments with plasmids and siRNAs were performed using
Lipofectamine Plus and Lipofectamine 2000, respectively, according to the
manufacturer’s instructions (Invitrogen).
Colony-formation assay. H1299 cells were transfected with Twist1 or Mcl-1
siRNAs for 24h. Cells were reseeded in 60-mm plates. Colony formation was
monitored over the subsequent 10 days. Colonies were stained using the Diff-Quick
kit (Sysmex, Hyogo, Japan).
ADP/ATP ratio assay. ADP/ATP ratios were determined using the Enzylight
ADP/ATP ratio assay kit (BioAssay, Hayward, CA, USA), according to the
manufacturer’s instructions.
Western blot analysis. Cell lysates and immunoprecipitates were separated
by SDS-PAGE and transferred to nitrocellulose membranes, followed by
immunoblotting with the speciﬁed primary antibodies and horseradish perox-
idase-conjugated secondary antibodies. Immunoreactive bands were visualized
with SuperSignal West Pico Chemiluminescent Substrates (Thermo Scientiﬁc
Pierce, Rockford, IL, USA).
Thefollowingantibodieswereused: p-AMPKa at Thr172 (2535),AMPKa(2532),
p-ACC at Ser79 (3661) and Bcl-2 (2876) p-ERK at Thr202/Tyr204 (9101), p-mTOR
at Ser2448 (2971), mTOR (2972) and p-S6K at Thr389 (9205), S6K (9202) and
p-S6 at Ser240/244 (4838), S6 (2217), cleaved PARP (9541) and p-AKT at Ser473
(9271) and AKT (9272), AKT2 (2964), Survivin (2808), a-Catenin (3236) and
b-Catenin (9562) obtained from Cell Signaling Technology, Vimentin (550513),
N-cadherin (610921) and Bcl-xL (610746) from BD Biosciences (San Diego, CA,
USA), p53 (NCL-p53-DO7) form Novocastra (Newcastle, UK), XIAP (610717) from
BD Transduction Laboratories (Lexington, KY, USA), Mcl-1 (sc-12756), p21
(sc-397), c-Myc (sc-40) and His (sc-8036) from Santa Cruz Biotechnology and
b-actin (A5316) from Sigma-Aldrich.
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